Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03-MedSci.cn

Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03

Stein, A; Lordick, F; Janjigian, YY; Oh, DY; Lee, KW; Steeghs, N; Chao, Y; Di Bartolomeo, M; Garcia, MD; Mohammad, NH; Mcadoo, W; Winter, M; Croydon, E; Lee, J

ONCOLOGY RESEARCH AND TREATMENT, 2022; 45 (SUPPL 3): 94

科室
- - 订阅+
  - 更多科室
工具
服务